Aspen Pharmacare agrees to sell European Ovestin rights to Ennogen for EUR 197 million

• Aspen Pharmacare will sell European commercialization rights and related intellectual property for women’s health product Ovestin to Ennogen for EUR 197 million.
• Related inventory is estimated at EUR 4 million; completion depends on Ennogen’s funding arrangements becoming unconditional.
• The disposal is expected to generate approximately ZAR 2 billion in profit, supporting a strategic focus on emerging markets.
• Manufacturing agreements provide for continued supply of Ovestin’s active ingredient and cream formulation for an initial 10 years.
• Ennogen will pay EUR 1 million monthly for strategic support services over five years.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspen Pharmacare Holdings Ltd. published the original content used to generate this news brief via SENS, the regulatory disclosure system operated by the Johannesburg Securities Exchange (JSE) (Ref. ID: S605915), on November 02, 2026, and is solely responsible for the information contained therein.